ImmunityBio Meets Endpoint In Second Indication Cohort In Bladder Cancer Trial

ImmunityBio Inc IBRX has announced that Papillary disease (Cohort B) of its Phase 2/3 study of intravesical BCG plus Anktiva met its primary endpoints with disease-free survival of 57% at 12 months.
Non-muscle invasive bladder cancer (NMIBC) makes up 75%-85% of all bladder cancers in the U.S.; approximately 90% of NMIBC cases are papillary.
Related: ImmunityBio Announces Updated Data From Ongoing Bladder Cancer Trial Showing Complete Response Rate Of 72%.
To date, 73 patients have enrolled in Cohort B with a median follow-up of 17.3 months.
At 18-months, the disease-free survival rate was 53%. Durable responses were noted.
There were zero immune- or treatment-related severe adverse events noted in the combined safety analysis of 154 patients in the trial.
Key patent allowed covering Anktiva intravesical use in bladder cancer with the term extending to 2035.
Price Action: IBRX shares are up 2.52% at $9.16 during the market session on the last check Tuesday.